Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus JENTADUETO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus JENTADUETO XR.
EMPAGLIFLOZIN AND LINAGLIPTIN vs JENTADUETO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
10 mg empagliflozin / 5 mg linagliptin orally once daily
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
None Documented
None Documented
Empagliflozin: terminal half-life ~12.4 hours, allowing once-daily dosing. Linagliptin: terminal half-life ~113-131 hours due to saturable binding to DPP-4, enabling once-daily dosing despite short plasma half-life.
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Empagliflozin: 54% excreted unchanged in urine (renal), 41% in feces (biliary/fecal). Linagliptin: 80% excreted unchanged in feces via enterohepatic circulation, <5% in urine.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor / Biguanide Combination